Abstract
Telmisartan (Micardis), is a highly selective angiotensin II type 1 receptor antagonist, which is approved for the treatment of high blood pressure i.e, hypertension, either as monotherapy or in combination with other antihypertensive agents such as example hydrochlorothiazide. The long elimination half-life of telmisartan ensures the drug provides effect decrease in blood BP across the entire 24-hour dosage interval. From the well-designed clinical trials and the clinical practice that indicates that telmisartan, either as monotherapy or in combination with other antihypertensive agents, provides long-term antihypertensive efficacy and is well tolerated in a broad spectrum of hypertensive patients, including the elderly and those with co-existing type 2 diabetes mellitus, metabolic syndrome and/or renal impairment. BP control is maintained throughout the 24-hour dosage interval, including during the last 6 hours of this period and it is recordable. Mainly in some conditions like pregnancy, renal impairment and in hepatic failure conditions it is not given.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
